Genedant Capital and SeaX Ventures have co-led the US$4 million pre-seed funding of RyboDyn, a San Diego-based biotech firm, aiming to advance cancer immunotherapies by targeting cancer-specific proteins.

The funding will support RyboDyn’s efforts to accelerate drug development, focusing on delivering innovative therapies for cancer patients across Asia, where there is a significant need for advanced immunotherapies.

While initially discovered in the United States, RyboDyn is expanding its research to Asia, partnering with local biopharma companies and academic institutions.